2
Clinical Trials associated with GamEvac-Lyo(Research Institute of Influenza, Sankt-Peterburg, Russian Federation)A Double-blind Randomized Placebo-controlled Study of Safety and Immunogenicity of Medicinal Product GamEvac-Lyo, Vector-Based Vaccine Against Ebola Virus Disease, Lyophilisate for Preparation of Solution for Intramuscular Injection
The purpose of this study is to evaluate immunogenicity and safety of medicinal product GamEvac-Lyo- Vector-Based Vaccine against Ebola Virus Disease
01 - GamEvac-Combi-2016 " International Multicenter Study of the Immunogenicity of Medicinal Product GamEvac-Combi - Combined Vector-Based Vaccine Against Ebola Virus Disease, 0.5 ml+0.5 ml/Dose "
The purpose of this study is to evaluate immunogenicity, epidemiological efficacy and safety of medicinal product GamEvac-Combi - Combined Vector-Based Vaccine against Ebola Virus Disease, 0.5 ml+0.5 ml/dose
100 Clinical Results associated with GamEvac-Lyo(Research Institute of Influenza, Sankt-Peterburg, Russian Federation)
100 Translational Medicine associated with GamEvac-Lyo(Research Institute of Influenza, Sankt-Peterburg, Russian Federation)
100 Patents (Medical) associated with GamEvac-Lyo(Research Institute of Influenza, Sankt-Peterburg, Russian Federation)
100 Deals associated with GamEvac-Lyo(Research Institute of Influenza, Sankt-Peterburg, Russian Federation)